6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone

CAS : 73963-72-1

Ref. 3D-FC03161

Informations sur le produit

• Nom: 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
• Synonymes: Cilostazol, 2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-, 6-[4-(1-Cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril, 6-[4-(1-Cyclohexyl-1H-Tetrazol-5-Yl)Butoxy]-3,4-Dihydro-2(1H)-Quinolinone, 6-[4-(1-Cyclohexyl-5-Tetrazolyl)Butoxy]-1,2,3,4-Tetrahydro-2-Oxoquinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one, Cilostazole, Opc 13013, Opc 21, Pletaal, Pletal

Description

Cilostazol is a drug that binds to ATP-binding cassette (ABC) transporters, which are proteins that transport molecules across membranes. It decreases the production of cyclic nucleotides and phosphodiesterase, which are important in the regulation of blood vessel tone. Cilostazol has been shown to be effective in treating heart failure and atherosclerosis. Cilostazol also inhibits cyclase activity, an enzyme involved in the synthesis of cyclic nucleotides, which leads to vasodilation by increasing the concentration of cAMP. The drug is available in both immediate-release and controlled-release preparations. Cilostazol can have serious side effects such as congestive heart failure or stroke if it is taken with other drugs that inhibit platelet aggregation such as aspirin or warfarin.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 369.46 g/mol
• Formule: C₂₀H₂₇N₅O₂
• Degré de pureté: Min. 95%
• Couleur/Forme: White Powder
• InChI: InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
• Code InChI: InChIKey=RRGUKTPIGVIEKM-UHFFFAOYSA-N
• SMILES: O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1